Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.

The emergence of immune checkpoint inhibitors to treat various forms of cancer is associated with acute kidney injury (AKI), often due to (severe) tubulointerstitial nephritis, although rarely also minimal change disease with ATN, ANCA-negative pauci-immune GN, anti-GBM disease and C3GN can occur. This study gives an overview of clinical features, histopathological findings, risk factors and outcomes of this complication of new treatment. Whereas previous reports have been limited to single-center data, the current study is multicentric and comprises 138 patients. Importantly, most patients (69%) were receiving concomitant medication known to cause TIN,  often PPIs (54%).